← Back to Clinical Trials
Recruiting NCT05114876

NCT05114876 Redesigning the Surgical Pathway (PROMoTE)

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05114876
Status Recruiting
Phase
Sponsor Sunnybrook Health Sciences Centre
Condition Delirium
Study Type INTERVENTIONAL
Enrollment 260 participants
Start Date 2021-12-13
Primary Completion 2025-12

Eligibility & Interventions

Sex All sexes
Min Age 60 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Multicomponent delirium-risk prevention bundle

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 260 participants in total. It began in 2021-12-13 with a primary completion date of 2025-12.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Cognitive complications, that is problems with thinking and memory, are incredibly common after surgery, occurring in 10-50% of all older surgical patients. These complications can take different forms, but one of the most common is postoperative delirium (POD), a short-term state of confusion. In addition to being stressful for patients and their families, POD is linked to longer hospital stays, increased costs, higher mortality rates and other problems after surgery. Despite this, POD is often not recognized by doctors and there are currently no effective medications to treat POD. However, simple strategies such as helping patients to sleep properly and remain hydrated, have been shown to help. This study is testing if a delirium-reduction program will reduce postoperative delirium (POD) in older surgical patients. The investigators will first test memory and thought processes before surgery to find people who are most likely to develop POD. Once these people have been identified, they will be enrolled in a program which includes recommendations for their care team (e.g. surgeon, anesthesiologist, nurses) as well as educational materials for them and their family related to things that can be done to prevent delirium. By identifying at-risk patients and making sure that their doctors and caregivers are aware of how to prevent delirium, the investigators expect that this study will make surgery safer for older surgical patients.

Eligibility Criteria

Inclusion Criteria: * ≥ 60 years old * Undergoing major elective surgery (e.g., intra-abdominal, retroperitoneal, major orthopedic) with an expected postoperative stay of at least 1 night * Evidence of cognitive impairment on baseline screening tests (i.e. any score \< 90 on CBB or \>10 on S-OMCT) Exclusion Criteria: * Patients undergoing cardiac surgery * Patients undergoing intracranial neurosurgery * Patients with known substance use disorder (verbally declared by patients) * Unlikely to comply with study assessment (e.g., no fixed address, without access to internet/computer/phone).

Contact & Investigator

Central Contact

Stephen Choi, MD, MSc

✉ stephen.choi@sunnybrook.ca

📞 416-480-4864

Principal Investigator

Stephen Choi, MD, MSc

PRINCIPAL INVESTIGATOR

Sunnybrook Health Sciences Centre

Frequently Asked Questions

Who can join the NCT05114876 clinical trial?

This trial is open to participants of all sexes, aged 60 Years or older, studying Delirium. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05114876 currently recruiting?

Yes, NCT05114876 is actively recruiting participants. Contact the research team at stephen.choi@sunnybrook.ca for enrollment information.

Where is the NCT05114876 trial being conducted?

This trial is being conducted at Toronto, Canada.

Who is sponsoring the NCT05114876 clinical trial?

NCT05114876 is sponsored by Sunnybrook Health Sciences Centre. The principal investigator is Stephen Choi, MD, MSc at Sunnybrook Health Sciences Centre. The trial plans to enroll 260 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology